Tags

Type your tag names separated by a space and hit enter

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Alzheimers Dement. 2022 04; 18(4):824-857.AD

Abstract

INTRODUCTION

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020.

METHODS

We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion.

RESULTS

Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity.

DISCUSSION

ADNI has had a profound impact in improving clinical trials for AD.

Links

PMC Free PDF

Authors+Show Affiliations

Veitch DP
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA. Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA.
Weiner MW
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA. Department of Radiology, University of California, San Francisco, San Francisco, California, USA. Department of Medicine, University of California, San Francisco, San Francisco, California, USA. Department of Psychiatry, University of California, San Francisco, San Francisco, California, USA. Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Aisen PS
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Beckett LA
Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, California, USA.
DeCarli C
Department of Neurology and Center for Neuroscience, University of California Davis, Davis, California, USA.
Green RC
Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute, Ariadne Labs, and Harvard Medical School, Boston, Massachusetts, USA.
Harvey D
Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, California, USA.
Jack CR
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jagust W
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.
Landau SM
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.
Morris JC
Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.
Okonkwo O
Wisconsin Alzheimer's Disease Research Center and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Perrin RJ
Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA. Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA. Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Petersen RC
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Rivera-Mindt M
Department of Psychology, Fordham University, New York, New York, USA.
Saykin AJ
Department of Radiology and Imaging Sciences and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Shaw LM
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Toga AW
Laboratory of Neuroimaging, USC Stevens Institute of Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Tosun D
Department of Radiology, University of California, San Francisco, San Francisco, California, USA.
Trojanowski JQ
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alzheimer's Disease Neuroimaging Initiative
No affiliation info available

MeSH

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionDisease ProgressionHumansNeuroimagingtau Proteins

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34581485

Citation

Veitch, Dallas P., et al. "Using the Alzheimer's Disease Neuroimaging Initiative to Improve Early Detection, Diagnosis, and Treatment of Alzheimer's Disease." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 18, no. 4, 2022, pp. 824-857.
Veitch DP, Weiner MW, Aisen PS, et al. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement. 2022;18(4):824-857.
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., Morris, J. C., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera-Mindt, M., Saykin, A. J., Shaw, L. M., Toga, A. W., Tosun, D., & Trojanowski, J. Q. (2022). Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 18(4), 824-857. https://doi.org/10.1002/alz.12422
Veitch DP, et al. Using the Alzheimer's Disease Neuroimaging Initiative to Improve Early Detection, Diagnosis, and Treatment of Alzheimer's Disease. Alzheimers Dement. 2022;18(4):824-857. PubMed PMID: 34581485.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. AU - Veitch,Dallas P, AU - Weiner,Michael W, AU - Aisen,Paul S, AU - Beckett,Laurel A, AU - DeCarli,Charles, AU - Green,Robert C, AU - Harvey,Danielle, AU - Jack,Clifford R,Jr AU - Jagust,William, AU - Landau,Susan M, AU - Morris,John C, AU - Okonkwo,Ozioma, AU - Perrin,Richard J, AU - Petersen,Ronald C, AU - Rivera-Mindt,Monica, AU - Saykin,Andrew J, AU - Shaw,Leslie M, AU - Toga,Arthur W, AU - Tosun,Duygu, AU - Trojanowski,John Q, AU - ,, Y1 - 2021/09/28/ PY - 2021/06/08/revised PY - 2021/02/01/received PY - 2021/06/09/accepted PY - 2021/9/29/pubmed PY - 2022/4/9/medline PY - 2021/9/28/entrez KW - AV1541 tau positron emission tomography KW - Alzheimer's disease KW - amyloid KW - disease progression KW - mild cognitive impairment KW - plasma biomarker KW - tau SP - 824 EP - 857 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 18 IS - 4 N2 - INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/34581485/Using_the_Alzheimer's_Disease_Neuroimaging_Initiative_to_improve_early_detection_diagnosis_and_treatment_of_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -